AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall.
AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall. The North Chicago, Illinois, company said late Wednesday that it will pay $261.25 a share for Pharmacyclics, which makes Imbruvica, a drug approved to treat 3 different types of blood cancers. That represents a premium of about 21% to the closing price of Pharmacyclics shares on Tuesday.
The stock had surged Wednesday after London's Financial Times, citing sources it did not name, reported that competing drugmaker Johnson & Johnson was close to buying Pharmacyclics. That report also cautioned that the J&J deal might unravel.
Read the complete article on ABC News: http://abcn.ws/1BaIYl6
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen